Pacific Biosciences of California, Inc. (PACB)
NASDAQ: PACB · Real-Time Price · USD
1.580
-0.130 (-7.60%)
At close: Feb 17, 2026, 4:00 PM EST
1.580
0.00 (-0.02%)
After-hours: Feb 17, 2026, 4:14 PM EST
PACB Revenue
In the year 2024, Pacific Biosciences of California had annual revenue of $11.70M, down -2.99%. Pacific Biosciences of California had revenue of $2.82M in the quarter ending December 31, 2024, a decrease of -6.97%.
Revenue (ttm)
$11.70M
Revenue Growth
-2.99%
P/S Ratio
3.21
Revenue / Employee
$278,270
Employees
575
Market Cap
477.01M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 11.70M | -361.00K | -2.99% |
| Dec 31, 2023 | 12.06M | -693.00K | -5.43% |
| Dec 31, 2022 | 12.75M | 970.00K | 8.23% |
| Dec 31, 2021 | 11.78M | 617.00K | 5.53% |
| Dec 31, 2020 | 11.17M | 1.87M | 20.09% |
| Dec 31, 2019 | 9.30M | 3.63M | 63.97% |
| Dec 31, 2018 | 5.67M | 1.49M | 35.74% |
| Dec 31, 2017 | 4.18M | 3.93M | 1,597.97% |
| Dec 31, 2016 | 246.00K | 99.00K | 67.35% |
| Dec 31, 2015 | 147.00K | 25.00K | 20.49% |
| Dec 31, 2014 | 122.00K | 74.00K | 154.17% |
| Dec 31, 2013 | 48.00K | -187.91K | -79.65% |
| Jul 31, 2012 | 235.91K | -885.26K | -78.96% |
| Jul 31, 2011 | 1.12M | -1.12M | -50.07% |
| Jul 31, 2010 | 2.25M | 975.74K | 76.84% |
| Jul 31, 2009 | 1.27M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Varex Imaging | 854.40M |
| Orthofix Medical | 818.06M |
| Bioventus | 563.83M |
| Tactile Systems Technology | 311.51M |
| Cerus | 199.19M |
| Cytek Biosciences | 196.83M |
| Standard BioTools | 169.74M |
| NeuroPace | 94.86M |
PACB News
- 3 days ago - Pacific Biosciences of California, Inc. (PACB) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 15 days ago - PacBio Completes Sale of Short-Read Sequencing Assets - GlobeNewsWire
- 20 days ago - PacBio: The Consumables Flywheel Is Turning. The Chart Wants Confirmation - Seeking Alpha
- 21 days ago - PacBio to Report Fourth Quarter and Full Year 2025 Financial Results on February 12, 2026 - GlobeNewsWire
- 5 weeks ago - Pacific Biosciences of California, Inc. (PACB) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 5 weeks ago - PacBio Announces Plans for Collaboration With n-Lorem Foundation and EspeRare to Advance Precision Therapies for Rare Genetic Diseases - GlobeNewsWire
- 5 weeks ago - PacBio HiFi Adopted as First-Line Sequencing Approach to Investigate Sudden Unexplained Death in Childhood (SUDC) - GlobeNewsWire
- 5 weeks ago - PacBio and UC Davis Researchers Introduce CiFi, a New Long-Read 3C Method That Enables Chromosome-Scale Assemblies from a Single SMRT Cell - GlobeNewsWire